Neutrophil CD64 as a Marker of Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Immunol Invest. 2016 Aug;45(6):490-503. doi: 10.1080/08820139.2016.1177540. Epub 2016 May 25.

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are responsible for most mortality in patients with chronic obstructive pulmonary disease (COPD) and are caused mainly by bacterial infection. We analyzed and compared neutrophil CD64 expression (using the ratio of CD64 level in neutrophils to that in lymphocytes as an index), serum C-reactive protein (CRP), procalcitonin (PCT) levels, white blood cell (WBC) count, and neutrophil percentage among healthy subjects and patients with stable COPD or AECOPD. Compared with patients with COPD and healthy subjects, patients with AECOPD demonstrated significantly increased CD64 index, CRP, PCT, WBC count, and neutrophil percentage. Interestingly, CD64 index and PCT were both significantly higher in patients with AECOPD with positive bacterial sputum culture than those with negative culture. Furthermore, CD64 index and PCT were positively correlated in AECOPD, and there was also correlation between CD64 index and CRP, WBC, and neutrophil percentage. These data suggest that CD64 index is a relevant marker of bacterial infection in AECOPD. We divided patients with AECOPD into CD64-guided group and conventional treatment group. In CD64-guided group, clinicians prescribed antibiotics based on CD64 index; while in the conventional treatment group, clinicians relied on experience and clinical symptoms to determine the necessity for antibiotics. We found that the efficacy of antibiotic treatment in CD64-guided group was significantly improved compared with the conventional treatment group, including reduction of hospital stays and cost and shortened antibiotic treatment duration. Thus, the CD64 index has important diagnostic and therapeutic implications for antibiotic treatment of patients with AECOPD.

Keywords: Antibiotic treatment; diagnosis; efficacy; peripheral blood.

MeSH terms

  • Acute Disease
  • Aged
  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / therapeutic use
  • Biomarkers / blood
  • C-Reactive Protein / immunology
  • C-Reactive Protein / metabolism
  • Calcitonin / blood
  • Calcitonin / immunology
  • Case-Control Studies
  • Evidence-Based Medicine
  • Female
  • Gram-Negative Bacterial Infections / complications
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / immunology*
  • Gram-Negative Bacterial Infections / microbiology
  • Gram-Positive Bacterial Infections / complications
  • Gram-Positive Bacterial Infections / drug therapy
  • Gram-Positive Bacterial Infections / immunology*
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Length of Stay / economics
  • Leukocyte Count
  • Lymphocytes / drug effects
  • Lymphocytes / immunology*
  • Lymphocytes / microbiology
  • Lymphocytes / pathology
  • Male
  • Middle Aged
  • Neutrophils / drug effects
  • Neutrophils / immunology*
  • Neutrophils / microbiology
  • Neutrophils / pathology
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / immunology*
  • Pulmonary Disease, Chronic Obstructive / microbiology
  • Receptors, IgG / blood
  • Receptors, IgG / immunology

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Receptors, IgG
  • Calcitonin
  • C-Reactive Protein